Altruism and innovation in health care

Journal of Law and Economics

Volumn 53, Issue 3, 2010, Pages 497-518

  Jena, Anupam B ^a   Mechoulan, Stéphane ^b   Philipson, Tomas J ^c  

^a HARVARD UNIVERSITY   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79954473061     PISSN: 00222186     EISSN: None     Source Type: Journal    
DOI: 10.1086/648383     Document Type: Article

References (45)

1. Acemoglu, Daron, and Joshua Linn. 2004. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics 119:1049-90.
2. Anderson, Roy M., and Robert M. May. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press.
3. Arrow, Kenneth. 1961. Economic Welfare and the Allocation of Research for Invention. Pp. 609-26 in The Rate and Direction of Inventive Activity: Economic and Social Factors, edited by Richard Nelson. Princeton, N.J.: Princeton University Press.
4. Becker, Gary, Tomas Philipson, and Rodrigo Soares. 2005. The Quantity and Quality of Life and the Evolution of World Inequality. American Economic Review 95:277-91.
5. Caves, Richard, Michael Whinston, and Mark Hurwitz. 1991. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry. Pp. 1-66 in Brookings Papers on Economic Activity, Microeconomics 1991, edited by Clifford Winston and Martin Neil Baily. Washington, D.C.: Brookings Institution Press.
6. Commission on Macroeconomics and Health. 2001. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization.
7. Cutler, David, Genia Long, Ernst R. Berndt, Jimmy Royer, Andrée-Anne Fournier, Alicia Sasser, and Pierre Cremleux. 2007. The Value of Anti-hypertensive Drugs: A Perspective on Medical Innovation. Health Affairs 26(1):97-110.
8. Cutler, David, and Mark McClellan. 2001. Is Technological Change in Medicine Worth It? Health Affairs 20(5):11-29.
9. Cutler, David, and Ellen Meara. 2000. The Technology of Birth: Is It Worth It? Forum for Health Economics and Policy, Frontiers in Health Policy Research 3, art. 3. http://www.bepress.com/fhep/3/3/.
10. Cutler, David, Allison Rosen, and Sandeep Vijan. 2006. The Value of Medical Spending in the United States, 1960-2000. New England Journal of Medicine 355:920-27.
11. Finkelstein, Amy. 2004. Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry. Quarterly Journal of Economics 119:527-64.
12. Garber, Alan, Charles Jones, and Paul Romer. 2006. Insurance and Incentives for Medical Innovation. NBER Working Paper No. 12080. National Bureau of Economic Research, Cambridge, Mass.
13. Grabowski, Henry. 2003. Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act. Working paper. Duke University, Department of Economics, Durham, N.C.
14. Grossman, Gene, and Edwin Lai. 2002. International Protection of IP. NBER Working Paper No. 8704. National Bureau of Economic Research, Cambridge, Mass.
15. Hollis, Aidan. 2005. An Efficient Reward System for Pharmaceutical Innovation. Working paper. University of Calgary, Department of Economics, Calgary.
16. Jena, Anupam B., and Tomas Philipson. 2008a. Cost-Effectiveness Analysis and Innovation. Journal of Health Economics 27:1224-36.
17. Jena, Anupam B., and Tomas Philipson. 2008b. Innovation and Technology Adoption in Health Care Markets. Washington, D.C.: American Enterprise Institute Press.
18. Jones, Charles, and John Williams. 2000. Too Much of a Good Thing? The Economics of Investment in R&D. Journal of Economic Growth 5:65-85.
19. Kaiser Commission on Medicaid and the Uninsured. 2006. Medicaid and Long-Term Care Services. Publication No. 2186-04. Washington, D.C.: Kaiser Family Foundation.
20. Kanter, James. 2005. Roche Offers to Negotiate on Flu Drug. New York Times, October 19.
21. Kates, Jennifer, and Alyssa Wilson. 2004. Medicaid and HIV/AIDS. HIV/AIDS Policy Fact Sheet No. 7172. Henry J. Kaiser Family Foundation, Menlo Park, Calif. http://www.kff.org/medicaid/upload/Fact-Sheet-Medicaid-and-HIV-AIDS.pdf.
22. Kremer, Michael. 2002. Pharmaceuticals and the Developing World. Journal of Economic Perspectives 16(4):67-90.
23. Kremer, Michael, and Rachel Glennerster. 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, N.J.: Princeton University Press.
24. Laffont, J.-J. 1987. Externalities. Pp. 263-65 in The New Palgrave: A Dictionary of Economics, edited by John Eatwell, Murray Milgate, and Peter Newman. London: Macmillan.
25. Lanjouw, Jean. 2002. A New Global Patent Regime for Diseases: U.S. and International Legal Issues. Harvard Journal of Law and Technology 16:85-124.
26. Lichtenberg, Frank R. 2006. The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditure: An Assessment Based on Aggregate U.S. Time Series Data. Expert Review of Pharmacoeconomics and Outcomes Research 6:425-36.
27. Newhouse, Joseph P. 1992. Medical Care Costs: How Much Welfare Loss? Journal of Economic Perspectives 6(3):3-21.
28. Nordhaus, William D. 1969. Invention, Growth, and Welfare: A Theoretical Treatment of Technological Change. Cambridge, Mass.: MIT Press.
29. Nordhaus, William D. 1972. The Optimum Life of a Patent: Reply. American Economic Review 62:428-31.
30. Outterson, Kevin. 2005. Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets. Yale Journal of Health Policy, Law, and Ethics 5:193-286.
31. Parry, Ian. 1995. Optimal Pollution Taxes and Endogenous Technological Change. Resource and Energy Economics 17:69-85.
32. Parry, Ian, William Pizer, and Carolyn Fischer. 2000. How Important Is Technological Innovation in Protecting the Environment? Discussion Paper No. 00-15. Resources for the Future, Washington, D.C.
33. Philipson, Tomas. 2000. Economic Epidemiology and Infectious Diseases. Pp. 1761-1802 in Handbook of Health Economics, vol. 1B, edited by Anthony J. Culyer and Joseph P. Newhouse. New York: North-Holland.
34. Philipson, Tomas, and Anupam B. Jena. 2006. Who Benefits from New Medical Technologies? Estimates of Producer and Consumer Surpluses for HIV/AIDS Drugs. Forum for Health Economics and Policy, Biomedical Research and the Economy 9(2), art. 3. http://www.bepress.com/fhep/biomedical_research/3.
35. Philipson, Tomas, Anupam B. Jena, and Stéphane Mechoulan. 2011. Economic Efficiency and Incentives for R&D in Developing-World Disease. Working paper. University of Chicago, Harris School of Public Policy, Chicago.
36. Philipson, Tomas, and Stéphane Mechoulan. 2003. Intellectual Property and External Consumption Effects: Generalizations from Pharmaceutical Markets. NBER Working Paper No. 9598. National Bureau of Economic Research, Cambridge, Mass.
37. Pigou, Arthur C. 1932. Economics of Welfare. 4th ed. London: Macmillan.
38. Ringel, Jeanne, Susan Hosek, Ben Vollaard, and Sergej Mahnovski. 2002. The Elasticity of Demand for Health Care: A Review of the Literature and Its Application to the Military Health System. Santa Monica, Calif.: RAND.
39. Rosen, Allison B., David M. Cutler, Douglas M. Norton, Hsou Mei Hu, and Sandeep Vijan. 2007. The Value of Coronary Heart Disease Care for the Elderly, 1987-2002. Health Affairs 26:111-23.
40. Saint-Paul, Gilles. 2004. Are Intellectual Property Rights Unfair? Labour Economics 11: 129-44.
41. Scotchmer, Suzanne. 2006. Innovation and Incentives. Cambridge, Mass.: MIT Press.
42. Tirole, Jean. 1988. The Theory of Industrial Organization. Cambridge, Mass.: MIT Press.
43. Weinstein, Milton C. 1995. From Cost-Effectiveness Ratios to Resource Allocation: Where to Draw the Line? Pp. 77-97 in Valuing Health Care, edited by Frank A. Sloan. New York: Cambridge University Press.
44. Weisbrod, Burton. 1991. The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment. Journal of Economic Literature 29:523-52.
45. Wright, Brian D. 1983. The Economics of Invention Incentives: Patents, Prizes, and Research Contracts. American Economic Review 73:691-707.